| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 29 | 2024 | 5100 | 2.820 |
Why?
|
| Carcinoma, Pancreatic Ductal | 14 | 2024 | 1754 | 1.590 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 600 | 1.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2023 | 15874 | 1.380 |
Why?
|
| Biliary Tract Neoplasms | 4 | 2023 | 167 | 1.200 |
Why?
|
| Neoplasms | 29 | 2023 | 15180 | 1.150 |
Why?
|
| Paclitaxel | 10 | 2023 | 1998 | 1.130 |
Why?
|
| Immunotherapy | 8 | 2023 | 3347 | 1.120 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 235 | 1.080 |
Why?
|
| Deoxycytidine | 11 | 2023 | 1360 | 1.040 |
Why?
|
| Trifluridine | 2 | 2022 | 30 | 1.010 |
Why?
|
| Adenocarcinoma | 10 | 2023 | 7793 | 0.970 |
Why?
|
| Colorectal Neoplasms | 6 | 2024 | 3583 | 0.890 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2024 | 1338 | 0.840 |
Why?
|
| Esophageal Neoplasms | 5 | 2023 | 3170 | 0.830 |
Why?
|
| Antineoplastic Agents | 18 | 2023 | 14288 | 0.800 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2023 | 4768 | 0.800 |
Why?
|
| Bile Duct Neoplasms | 5 | 2023 | 495 | 0.750 |
Why?
|
| Anilides | 1 | 2022 | 267 | 0.720 |
Why?
|
| Bevacizumab | 4 | 2023 | 938 | 0.690 |
Why?
|
| Pyridines | 4 | 2022 | 1243 | 0.670 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2023 | 962 | 0.670 |
Why?
|
| Vaccines | 1 | 2024 | 392 | 0.650 |
Why?
|
| Humans | 106 | 2024 | 262248 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2022 | 3263 | 0.630 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2022 | 1054 | 0.590 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 61 | 0.590 |
Why?
|
| Cholangiocarcinoma | 4 | 2023 | 495 | 0.580 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.580 |
Why?
|
| Albumins | 5 | 2023 | 249 | 0.570 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2023 | 2342 | 0.560 |
Why?
|
| Dibenzazepines | 1 | 2016 | 4 | 0.550 |
Why?
|
| Interleukin-10 | 4 | 2020 | 485 | 0.550 |
Why?
|
| Stomach Neoplasms | 4 | 2023 | 2281 | 0.520 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2016 | 98 | 0.520 |
Why?
|
| Ifosfamide | 2 | 2014 | 346 | 0.520 |
Why?
|
| Alanine | 1 | 2016 | 239 | 0.510 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 621 | 0.510 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 482 | 0.510 |
Why?
|
| Enzyme Inhibitors | 3 | 2023 | 1879 | 0.510 |
Why?
|
| Esophagogastric Junction | 2 | 2023 | 545 | 0.510 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 210 | 0.490 |
Why?
|
| Gallbladder Neoplasms | 3 | 2023 | 245 | 0.480 |
Why?
|
| Maximum Tolerated Dose | 9 | 2023 | 1290 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.470 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.470 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2013 | 21 | 0.450 |
Why?
|
| Serum Albumin | 1 | 2014 | 251 | 0.450 |
Why?
|
| Benzopyrans | 1 | 2013 | 41 | 0.450 |
Why?
|
| Male | 58 | 2024 | 123338 | 0.440 |
Why?
|
| Leucovorin | 5 | 2020 | 333 | 0.440 |
Why?
|
| Middle Aged | 50 | 2024 | 86544 | 0.440 |
Why?
|
| Fluorouracil | 7 | 2021 | 1946 | 0.430 |
Why?
|
| Receptors, Notch | 1 | 2016 | 379 | 0.430 |
Why?
|
| Aged | 41 | 2023 | 70367 | 0.420 |
Why?
|
| Female | 59 | 2024 | 142293 | 0.410 |
Why?
|
| Multienzyme Complexes | 1 | 2013 | 216 | 0.410 |
Why?
|
| Prognosis | 16 | 2023 | 21737 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 4945 | 0.380 |
Why?
|
| Aged, 80 and over | 24 | 2022 | 29996 | 0.370 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2021 | 1250 | 0.370 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1389 | 0.360 |
Why?
|
| Germ Cells | 3 | 2022 | 338 | 0.360 |
Why?
|
| Anus Neoplasms | 1 | 2014 | 412 | 0.350 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 1247 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 591 | 0.340 |
Why?
|
| Pyrazoles | 4 | 2023 | 1479 | 0.340 |
Why?
|
| Brain Diseases | 1 | 2012 | 403 | 0.330 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 10348 | 0.330 |
Why?
|
| Adult | 34 | 2022 | 78179 | 0.330 |
Why?
|
| Quinolones | 3 | 2021 | 159 | 0.320 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2008 | 70 | 0.310 |
Why?
|
| Treatment Outcome | 20 | 2022 | 33028 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2334 | 0.310 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 37 | 0.310 |
Why?
|
| Pancreatectomy | 3 | 2021 | 655 | 0.310 |
Why?
|
| Drug Administration Schedule | 7 | 2019 | 3482 | 0.300 |
Why?
|
| Hypertension | 1 | 2016 | 1514 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6223 | 0.280 |
Why?
|
| Azepines | 2 | 2017 | 129 | 0.280 |
Why?
|
| Drugs, Investigational | 2 | 2017 | 135 | 0.280 |
Why?
|
| Aurora Kinase A | 2 | 2017 | 207 | 0.270 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 13669 | 0.270 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 224 | 0.270 |
Why?
|
| Receptor, ErbB-2 | 4 | 2023 | 2519 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 10067 | 0.260 |
Why?
|
| Aromatase Inhibitors | 1 | 2008 | 305 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2024 | 2062 | 0.260 |
Why?
|
| Survival Analysis | 6 | 2020 | 9195 | 0.260 |
Why?
|
| Disease-Free Survival | 6 | 2022 | 10021 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 5339 | 0.250 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 744 | 0.250 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 1541 | 0.250 |
Why?
|
| Precision Medicine | 3 | 2022 | 1160 | 0.250 |
Why?
|
| Piperazines | 3 | 2023 | 2098 | 0.250 |
Why?
|
| Phthalazines | 3 | 2023 | 253 | 0.240 |
Why?
|
| Capecitabine | 3 | 2022 | 388 | 0.240 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 11571 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 4386 | 0.230 |
Why?
|
| Retrospective Studies | 17 | 2023 | 38011 | 0.230 |
Why?
|
| Benzoxazoles | 1 | 2024 | 41 | 0.230 |
Why?
|
| Exanthema | 2 | 2024 | 210 | 0.230 |
Why?
|
| Mucositis | 1 | 2023 | 147 | 0.220 |
Why?
|
| Drug Combinations | 2 | 2022 | 621 | 0.220 |
Why?
|
| Hydrazines | 2 | 2022 | 208 | 0.220 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2860 | 0.210 |
Why?
|
| Leiomyosarcoma | 1 | 2024 | 224 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2021 | 5435 | 0.210 |
Why?
|
| Microsatellite Instability | 2 | 2021 | 400 | 0.210 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 33 | 0.200 |
Why?
|
| Pyrimidines | 3 | 2020 | 3538 | 0.200 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 200 | 0.200 |
Why?
|
| Stress, Psychological | 1 | 2009 | 1001 | 0.200 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2022 | 140 | 0.200 |
Why?
|
| Lymphopenia | 1 | 2023 | 199 | 0.200 |
Why?
|
| Celiac Plexus | 1 | 2021 | 13 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 2633 | 0.200 |
Why?
|
| Disease Progression | 3 | 2023 | 6693 | 0.200 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 165 | 0.200 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 37 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 1219 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 994 | 0.190 |
Why?
|
| Ovarian Neoplasms | 3 | 2024 | 4660 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 522 | 0.190 |
Why?
|
| Adenine | 1 | 2024 | 639 | 0.190 |
Why?
|
| Nitroimidazoles | 1 | 2021 | 100 | 0.190 |
Why?
|
| Thrombocytopenia | 2 | 2023 | 847 | 0.190 |
Why?
|
| Stomach | 1 | 2023 | 387 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 6607 | 0.180 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 297 | 0.180 |
Why?
|
| Karyopherins | 1 | 2021 | 135 | 0.180 |
Why?
|
| Metformin | 1 | 2024 | 378 | 0.180 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 120 | 0.180 |
Why?
|
| Young Adult | 11 | 2021 | 21494 | 0.170 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 15709 | 0.170 |
Why?
|
| Gene Amplification | 1 | 2022 | 730 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 242 | 0.170 |
Why?
|
| United States | 5 | 2020 | 15574 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 666 | 0.170 |
Why?
|
| Health Expenditures | 1 | 2021 | 211 | 0.160 |
Why?
|
| Organoplatinum Compounds | 2 | 2020 | 704 | 0.160 |
Why?
|
| Diamines | 1 | 2018 | 25 | 0.160 |
Why?
|
| Administration, Oral | 3 | 2018 | 1554 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 14913 | 0.150 |
Why?
|
| Peptides | 1 | 2024 | 1476 | 0.150 |
Why?
|
| Biomarkers | 5 | 2023 | 5055 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 483 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 986 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 591 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2021 | 428 | 0.150 |
Why?
|
| Itraconazole | 1 | 2017 | 77 | 0.150 |
Why?
|
| Esomeprazole | 1 | 2017 | 31 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 478 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 172 | 0.150 |
Why?
|
| Cadherins | 1 | 2020 | 663 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 1505 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 223 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2020 | 351 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 6932 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 584 | 0.140 |
Why?
|
| Triazoles | 1 | 2021 | 618 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2021 | 719 | 0.140 |
Why?
|
| Rifampin | 1 | 2017 | 192 | 0.140 |
Why?
|
| Uracil | 1 | 2016 | 64 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 740 | 0.140 |
Why?
|
| Cancer Pain | 1 | 2021 | 313 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 336 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 881 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 2152 | 0.130 |
Why?
|
| Psychometrics | 1 | 2020 | 950 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1350 | 0.130 |
Why?
|
| Resorcinols | 1 | 2015 | 27 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2016 | 413 | 0.130 |
Why?
|
| Epidemiologic Methods | 2 | 2021 | 253 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2017 | 699 | 0.130 |
Why?
|
| Survival Rate | 5 | 2021 | 12239 | 0.130 |
Why?
|
| Gemfibrozil | 1 | 2014 | 6 | 0.130 |
Why?
|
| Diarrhea | 3 | 2024 | 689 | 0.130 |
Why?
|
| Cetuximab | 2 | 2014 | 472 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 856 | 0.130 |
Why?
|
| Ketoconazole | 1 | 2014 | 34 | 0.130 |
Why?
|
| Isoxazoles | 1 | 2015 | 81 | 0.130 |
Why?
|
| CA-19-9 Antigen | 3 | 2022 | 146 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1388 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2021 | 1529 | 0.120 |
Why?
|
| Electrocardiography | 2 | 2017 | 1145 | 0.120 |
Why?
|
| Cisplatin | 3 | 2021 | 2432 | 0.120 |
Why?
|
| Isoflavones | 1 | 2014 | 73 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1332 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 196 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 658 | 0.120 |
Why?
|
| Bayes Theorem | 3 | 2023 | 1034 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1024 | 0.120 |
Why?
|
| Oximes | 1 | 2014 | 176 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 1690 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3755 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 2 | 2021 | 3975 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2020 | 2321 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2022 | 1826 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 1294 | 0.110 |
Why?
|
| Neoplasm Metastasis | 6 | 2022 | 5124 | 0.110 |
Why?
|
| Oncolytic Virotherapy | 1 | 2016 | 252 | 0.110 |
Why?
|
| Genomics | 2 | 2021 | 2744 | 0.110 |
Why?
|
| Mitomycin | 1 | 2014 | 206 | 0.110 |
Why?
|
| Mutation | 6 | 2023 | 15167 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1047 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2085 | 0.110 |
Why?
|
| Carboplatin | 1 | 2016 | 823 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2020 | 12923 | 0.110 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 804 | 0.110 |
Why?
|
| Gingival Neoplasms | 1 | 2012 | 6 | 0.110 |
Why?
|
| DNA Repair | 1 | 2020 | 1870 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 3983 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2018 | 1991 | 0.100 |
Why?
|
| Trastuzumab | 2 | 2020 | 697 | 0.100 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 3018 | 0.100 |
Why?
|
| Plasmacytoma | 1 | 2013 | 111 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 4980 | 0.100 |
Why?
|
| Quality of Life | 2 | 2023 | 4582 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 2012 | 129 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1295 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1596 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2059 | 0.100 |
Why?
|
| Adolescent | 4 | 2023 | 31239 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2016 | 1681 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 608 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 4355 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1765 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 7566 | 0.090 |
Why?
|
| Bone Marrow Purging | 1 | 2009 | 86 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2028 | 0.090 |
Why?
|
| Heart | 1 | 2016 | 1227 | 0.090 |
Why?
|
| Imidazoles | 1 | 2014 | 1003 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 1266 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2022 | 603 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2992 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2017 | 11972 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 491 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1284 | 0.080 |
Why?
|
| Mitochondria | 1 | 2014 | 1281 | 0.080 |
Why?
|
| Transplantation Chimera | 1 | 2007 | 163 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 12984 | 0.070 |
Why?
|
| Cytokines | 1 | 2016 | 2824 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2008 | 181 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2021 | 9282 | 0.070 |
Why?
|
| Nausea | 2 | 2023 | 525 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3891 | 0.070 |
Why?
|
| Safety | 2 | 2021 | 464 | 0.070 |
Why?
|
| Melanoma | 2 | 2021 | 5319 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 1392 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 541 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2008 | 261 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2012 | 943 | 0.060 |
Why?
|
| Busulfan | 1 | 2009 | 766 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4563 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5538 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4655 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 638 | 0.060 |
Why?
|
| Life Style | 1 | 2008 | 616 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2016 | 6900 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5778 | 0.060 |
Why?
|
| Health Promotion | 1 | 2008 | 504 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2023 | 26 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2018 | 1148 | 0.060 |
Why?
|
| Quinazolines | 1 | 2008 | 924 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2008 | 791 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2024 | 262 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 1925 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4903 | 0.050 |
Why?
|
| Incidence | 2 | 2012 | 5713 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 263 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1667 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 3080 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 573 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 158 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 254 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 403 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 372 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.050 |
Why?
|
| Remission Induction | 1 | 2007 | 3584 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 2892 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 271 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 1379 | 0.050 |
Why?
|
| Taxoids | 2 | 2016 | 970 | 0.050 |
Why?
|
| Indium Radioisotopes | 1 | 2020 | 65 | 0.050 |
Why?
|
| Ischemia | 1 | 2023 | 395 | 0.050 |
Why?
|
| Topotecan | 1 | 2021 | 239 | 0.050 |
Why?
|
| Benzazepines | 1 | 2021 | 109 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 842 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 321 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 356 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 289 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 160 | 0.050 |
Why?
|
| Income | 1 | 2021 | 225 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 266 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2023 | 291 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2020 | 223 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2022 | 252 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2020 | 267 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 1 | 2020 | 178 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 6308 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 344 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 213 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 665 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 612 | 0.040 |
Why?
|
| Granzymes | 1 | 2018 | 91 | 0.040 |
Why?
|
| Pyrazines | 1 | 2021 | 495 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 101 | 0.040 |
Why?
|
| Everolimus | 1 | 2020 | 415 | 0.040 |
Why?
|
| Fatigue | 2 | 2016 | 1239 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 674 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2605 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2232 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5724 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 503 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 1001 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 927 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 717 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 59489 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 1684 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 453 | 0.040 |
Why?
|
| Capsules | 1 | 2016 | 55 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2016 | 50 | 0.040 |
Why?
|
| Tablets | 1 | 2016 | 56 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2016 | 71 | 0.040 |
Why?
|
| Mammalian orthoreovirus 3 | 1 | 2016 | 10 | 0.040 |
Why?
|
| Testis | 1 | 2020 | 716 | 0.030 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2016 | 66 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 334 | 0.030 |
Why?
|
| Thymine | 1 | 2016 | 46 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1145 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 284 | 0.030 |
Why?
|
| Radiography | 1 | 2020 | 1900 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2016 | 113 | 0.030 |
Why?
|
| Risk Factors | 2 | 2012 | 17622 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 802 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C8 Inhibitors | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pain Management | 1 | 2021 | 670 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1186 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2021 | 1009 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 438 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 28 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 462 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2008 | 8225 | 0.030 |
Why?
|
| Pregnancy | 1 | 2008 | 7549 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 158 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2023 | 2297 | 0.030 |
Why?
|
| Uveal Neoplasms | 1 | 2016 | 176 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 342 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 8882 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 258 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 520 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 715 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 739 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2016 | 183 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 34393 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 4323 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 499 | 0.030 |
Why?
|
| Warfarin | 1 | 2014 | 152 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2022 | 1424 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2014 | 555 | 0.030 |
Why?
|
| Jaundice, Obstructive | 1 | 2013 | 16 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 5009 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 877 | 0.030 |
Why?
|
| Suramin | 1 | 2012 | 14 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1826 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 1448 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 7545 | 0.030 |
Why?
|
| Genome, Human | 1 | 2020 | 1868 | 0.030 |
Why?
|
| Leukopenia | 1 | 2012 | 151 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 222 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 1534 | 0.030 |
Why?
|
| Kidney | 1 | 2020 | 2144 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2015 | 815 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 1341 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 2915 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1109 | 0.020 |
Why?
|
| Anemia | 1 | 2016 | 690 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 2904 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 5598 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2267 | 0.020 |
Why?
|
| Palliative Care | 1 | 2021 | 2031 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 691 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2288 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3167 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4337 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 791 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3233 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 6927 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 1818 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3563 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8885 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7241 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6104 | 0.020 |
Why?
|